AJP - Heart AJP: Heart and Circulatory Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 288: H896-H903, 2005. First published October 7, 2004; doi:10.1152/ajpheart.00407.2004
0363-6135/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/2/H896    most recent
00407.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rundell, V. L. M.
Right arrow Articles by de Tombe, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rundell, V. L. M.
Right arrow Articles by de Tombe, P. P.

Impact of {beta}-myosin heavy chain isoform expression on cross-bridge cycling kinetics

Veronica L. M. Rundell, Vlasios Manaves, Anne F. Martin, and Pieter P. de Tombe

Center for Cardiovascular Research, Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, Illinois

Submitted 3 May 2004 ; accepted in final form 5 October 2004


    ABSTRACT
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Myosin heavy chain (MHC) isoforms {alpha} and {beta} have intrinsically different ATP hydrolysis activities (ATPase) and therefore cross-bridge cycling rates in solution. There is considerable evidence of altered MHC expression in rodent cardiac disease models; however, the effect of incremental {beta}-MHC expression over a wide range on the rate of high-strain, isometric cross-bridge cycling is yet to be ascertained. We treated male rats with 6-propyl-2-thiouracil (PTU; 0.8 g/l in drinking water) for short intervals (6, 11, 16, and 21 days) to generate cardiac MHC patterns in transition from predominantly {alpha}-MHC to predominantly {beta}-MHC. Steady-state calcium-dependent tension development and tension-dependent ATP consumption (tension cost; proportional to cross-bridge cycling) were measured in chemically permeabilized (skinned) right ventricular muscles at 20°C. To assess dynamic cross-bridge cycling kinetics, the rate of force redevelopment (ktr) was determined after rapid release-restretch of fully activated muscles. MHC isoform content in each experimental muscle was measured by SDS-PAGE and densitometry. {alpha}-MHC content decreased significantly and progressively with length of PTU treatment [68 ± 5%, 58 ± 4%, 37 ± 4%, and 27 ± 6% for 6, 11, 16, and 21 days, respectively; P < 0.001 (ANOVA)]. Tension cost decreased, linearly, with decreased {alpha}-MHC content [6.7 ± 0.4, 5.6 ± 0.5, 4.0 ± 0.4, and 3.9 ± 0.3 ATPase/tension for 6, 11, 16, and 21 days, respectively; P < 0.001 (ANOVA)]. Likewise, ktr was significantly and progressively depressed with length of PTU treatment [11.1 ± 0.6, 9.1 ± 0.5, 8.2 ± 0.7, and 6.2 ± 0.3 s–1 for 6, 11, 16, and 21 days, respectively; P < 0.05 (ANOVA)] Thus cross-bridge cycling, under high strain, for {alpha}-MHC is three times higher than for {beta}-MHC. Furthermore, under isometric conditions, {alpha}-MHC and {beta}-MHC cross bridges hydrolyze ATP independently of one another.

rate of force redevelopment; sodium dodecyl sulfate-polyacrylamide gel electrophoresis; mammalian myocardium


THE SPEED WITH WHICH MUSCLE shortens is correlated to the intrinsic ATP hydrolysis activity of myosin (1). In vertebrate striated muscle there are several isoforms of myosin heavy chain (MHC); however, only two cardiac isoforms are expressed, {alpha}-MHC and {beta}-MHC, which share 93% homology in the rat (26). Myofibrillar and myosin ATPase studies have reported that {alpha}-MHC has a higher ATPase activity than {beta}-MHC; however, these measurements were made in low- or no-strain preparations (34). The maximal shortening velocity, which is correlated to the ATP hydrolysis rate, is significantly higher in fibers that contain a higher proportion of {alpha}-MHC (5, 36). Contractile power is increased in myocardial tissue containing high {alpha}-MHC as opposed to tissues with even a small amount of {beta}-MHC (17, 18). Although the isometric tension generated by both isoforms is roughly identical (Refs. 16, 29, 41, but see Refs. 15 and 40), the cross-bridge cycling rate and amount of ATP consumed to generate a given level of tension development are significantly disparate, with {alpha}-MHC having an ATP hydrolysis rate three times that of {beta}-MHC and a duty cycle that is nearly half (16, 40). This indicates that {beta}-MHC is the more energetically economical isoform. Therefore, although MHC composition can affect cardiac contractility, it is unclear whether there is mechanical advantage in the expression of one isoform over the other.

Ventricular MHC isoforms are expressed differentially across species and also during development within the same species. Likewise, it is well documented that there are changes in cardiac MHC isoform population in many mammals with developmental stage, aging, thyroid state, and cardiac disease (19, 27, 36, 38). Species-related differences in MHC isoform content are attributed to heart rate differentials that exist between small and large mammals. Small mammals may have developed high heart rates to maintain sufficient arterial diastolic pressure to allow for coronary perfusion with the constraint that the heart and arteries be of minimum size to maximize efficiency (8, 42). In normal adult large mammals (pigs, cats, dogs, and humans) ventricular {beta}-MHC content is high, whereas in smaller mammals (mouse and rat) {alpha}-MHC is the predominant isoform. The high levels of {alpha}-MHC content in small mammals are considered adaptational because the faster ATP hydrolysis rate of {alpha}-MHC facilitates the extremely rapid rates of cardiac contraction and relaxation present in these animals (16). As a result, the use of rodent models to study cardiac disease is confounded first by investigating cardiac tissue, which predominantly contains the faster {alpha}-MHC, unlike human tissue, and second by the increased expression of {beta}-MHC that naturally occurs as a consequence of cardiac insult.

There is considerable evidence of altered MHC expression in rodent models of cardiac disease (14, 23, 28, 32, 38); however, the effect of incremental {beta}-MHC expression over a wide range on the rate of cross-bridge cycling is yet to be ascertained. Recently, van der Velden and colleagues (41) demonstrated a significant, and linear, decrease in cross-bridge cycling rate in skinned fibers prepared from young and old guinea pigs. Guinea pigs, however, predominantly express the {beta}-MHC isoform, even in juvenile states, such that the range of {alpha}-MHC content was small in that study, only between 5% and 30%. Thus the question remains as to whether or not cross-bridge cycling rate is a linear function over a wide range of MHC isoform expression. 6-Propyl-2-thiouracil (PTU) interferes with the production of thyroid hormone (T3) by blocking iodination of thyroglobulin and also by blocking the coupling of diiodothyronine and monoiodothyronine (21). As a result, animals treated with PTU are rendered hypothyroid, silencing the {alpha}-MHC gene promoter and subsequent transcription and translation of the {beta}-MHC gene (9, 26). As the turnover rate of myosin in the heart is relatively slow (5.4 days; Ref. 25), administration of the drug for short periods of time produces cardiac tissue that contains variable amounts of {beta}-MHC. We have adapted the method of Laemmli (22), utilizing a low cross-linking acrylamide solution as previously described (12, 24). Modification of electrophoresis conditions enabled us to improve the resolution of separation between {alpha}-MHC and {beta}-MHC not just in rat, but also in human, porcine, baboon, rabbit, guinea pig, and murine myocardial tissue. Using this improved method of gel electrophoresis allowed us to accurately determine MHC isoform content in the individual skinned muscles that were used for chemomechanical experiments, thus allowing for a direct correlation between cross-bridge cycling kinetics and MHC isoform content.


    METHODS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals were treated and housed in accordance with the Animal Care and Use Committee guidelines at the University of Illinois at Chicago Biologic Resources Laboratory. Male Lewis Brown Norway-F1 rats (Harlan Laboratories) were treated with PTU (0.8 g/l in drinking water) for short intervals (6, 11, 16, and 21 days) to generate cardiac MHC patterns in transition from {alpha}-MHC to {beta}-MHC expression. Treatment with PTU in this manner leads to a rapid reduction in circulating T3 levels in the rat, as we showed previously (5). Animals were anesthetized by intraperitoneal injection of pentobarbital sodium (200 mg/kg), and hearts were rapidly excised. Body and heart weights were obtained at the time of death. Right ventricular (RV) trabeculae (muscles) were dissected free and incubated overnight at 4°C in low-calcium solution containing 1% Triton X-100 to chemically remove all cellular membranes, which contained (in mM) 20 EGTA, 10 creatine phosphate, 100 N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 5.93 ATP, 6.6 magnesium chloride, and 20.7 potassium proprionate, at pH 7.0. Once permeabilized, muscles were attached to hooks mounted on a force transducer (AE 801 SensoNor) and a motor arm (model 403, Cambridge Scientific) in the experimental apparatus by aluminum T clips, as previously described (4). The sarcomere length (SL) in each muscle was set to 2.3 µm by laser diffraction. Briefly, a 10-mW HeNe laser was focused onto the muscle (~300-µm spot size), and the resulting diffraction pattern was projected onto a calibrated screen. Muscles were stretched by micromanipulators to set SL to 2.3 µm. SL was checked at regular intervals throughout the experiment and readjusted as required. In general, SL was stable after a first test contraction at full activation. Muscles in which a stable SL was not observed were discarded. The muscle dimensions were measured under a light microscope at x40 power. Thickness of the preparation was measured at x40 power with a 45° mirror positioned adjacent to the fiber. Dimensions were measured at three positions along the length of the muscle, and cross-sectional area was calculated from the average dimensions, assuming an elliptical shape. Muscles were exposed to a range of calcium solutions obtained by proportional mixing of activating and relaxing solutions, and the force generated and ATP consumed were measured simultaneously during contraction as previously described (4).

Mechanical experiments. Calcium-dependent tension and tension-dependent ATP consumption were measured in skinned RV trabeculae at SL of 2.3 µm at 20°C. Additionally, to gain a measure of the dynamic turnover rate of cross bridges, the rate of force redevelopment (ktr) was measured in high-calcium full-activating solution. In all preparations high-frequency stiffness was assessed by recording the strain elicited by rapid oscillation (500 Hz) of the preparation by 1% of the muscle length and sampled and analyzed by a dual-phase lock-in amplifier (Stanford Research Systems). ATP consumption was measured with an enzyme-coupled ultraviolet (UV) light absorbance assay (4, 7, 13). Briefly, ADP generated by the muscle was rephosphorylated to ATP by the action of pyruvate kinase (PK; 0.5 mg/ml) with phosphoenolpyruvate (PEP; 10 mM) as substrate, causing the formation of pyruvate. Next, pyruvate was converted to lactate by the action of lactate dehydrogenase (LDH; 0.05 mg/ml) and the substrate NADH (~1 mM) to form NAD+. All enzymes and substrates were added at sufficient concentration such that the reactions proceeded rapidly and far from equilibrium to ensure an effectively stoichiometric reaction system. Because NADH absorbs UV light (340 nm) whereas NAD+ does not, the system allows for the determination of ATP consumption rate by measurement of NADH absorbance. Individual experimental examples are shown in Fig. 1A (NADH absorbance record at top and matched force trace at bottom). It is clear that NADH absorbance decreases immediately on incubation of the muscle in activating levels of calcium (50 µM) and stabilizes on its removal from the bath. A series of calibration steps is performed with every record by stepwise injection of 250 pmol of ADP. In the analysis of the raw record, the height of each step is measured and the average drop in absorbance is determined for each 250-pmol step of ADP. The slope of the NADH absorbance recorded during the contraction is then measured with this calibrated signal. As this calibration is done for each experimental contraction, we are able to accurately assess the concentration of NADH consumed in the ATP regeneration process and therefore also the ATP consumption because they are stoichiometrically linked. The calibrating steps also illustrate that during contraction, cross-bridge ADP production is the rate-limiting step in this measurement, not the enzyme cascade.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1. A: original NADH and force traces from right ventricular muscles of rats treated 6 and 21 days with 6-propyl-2-thiouracil (PTU). Top: NADH signals recorded from 1 muscle from the 6-day PTU treatment group (left) and 1 muscle from the 21-day PTU treatment group (right) at maximum activating calcium (50 µM). Bottom: matched force traces for these muscles. As the muscle is incubated in calcium, force is generated and the NADH signal declines. ATP consumption is stoichiometrically coupled to NADH consumption by the actions of the enzymes pyruvate kinase and lactate dehydrogenase; thus the slope of the NADH trace is proportional to ATP consumption. When the muscle is removed to a relaxing solution, force drops to preactivation levels and NADH consumption, and therefore ATP consumption essentially stops. A series of ADP injections (250 pmol), indicated by arrows, are made into the measuring chamber for calibration of the NADH signal. B: raw traces of the rate of force redevelopment (ktr) maneuvers of the muscles illustrated in A. The top line represents the 6-day PTU treatment muscle, and the bottom line represents the 21-day PTU treatment muscle. The slope of the rate of tension rise following the rapid release-restretch of the muscle is fit by a single-exponential equation. It is apparent that the ktr of the 21-day PTU treatment muscle is significantly slower than that of the 6-day PTU treatment muscle (6-day PTU: 11.06 s–1, R = 0.99; 21-day PTU: 5.8 s–1, R = 0.99). C: line fits of the ktr data represented in B. The data have been normalized for illustration; however, the fit parameters were taken from the raw data trace. The top line indicates 6-day PTU treatment, and the bottom line indicates 21-day PTU treatment.

 
The experimental apparatus consisted of a cooled aluminum block in which three baths were placed. The preparation (muscle, force transducer, and motor) was mounted on a sliding arm such that it could be rapidly lifted and placed inside each of the three baths. The first bath contained relaxing solution, the second contained preactivating solution, and the third bath was the measuring chamber, which contained activating solution that could be titrated with relaxing solution to generate a range of calcium solutions to elicit variable levels of contraction. The fiber was moved sequentially from relaxing to preactivating baths and then to the measuring bath for determination of steady-state force development and ATP consumption. After steady-state force development and data acquisition, the muscle was returned to the relaxing bath until force returned to preactivation levels. At that time, it was placed in the preactivating bath to prepare for the next calcium incubation. In all, these fibers were exposed to 8–10 contractions during the course of an experiment. The final contraction was in saturating calcium, and the preparation was discarded if the developed tension was decreased by >10% from the first contraction. Activating solution contained (in mM) 20 Ca-EGTA, 1.55 potassium proprionate, 6.59 magnesium chloride, 100 BES, 5 sodium azide, 1 DTT, 10 PEP, 0.01 leupeptin, 0.001 pepstatin, 0.01 oligomycin, 0.01 PMSF, and 0.01 A2P5. Relaxing solution was identical except it contained (in mM) 20 EGTA, 21.2 potassium proprionate, and 7.11 MgCl2. Preactivating solution contained (in mM) 0.5 EGTA, 19.5 hexamethylenediamine-N,N,N',N'-tetraacetate (Fluka), and 21.8 potassium proprionate. All solutions contained 0.5 mg/ml PK (386 U/mg) and 0.05 mg/ml LDH (880 U/mg) (Sigma, St. Louis, MO). All solutions had an ionic strength of 200 mM and 5 mM free ATP and 1 mM free magnesium as determined by the methods of Fabiato and Fabiato (10), assuming an apparent stability constant of the Ca2+-EGTA complex of 106.58 (4).

The final maximal activating contraction was accompanied by a rapid release-restretch protocol that allowed for measurement of ktr, to further investigate the kinetics of cross-bridge cycling. This method is similar to that of Brenner and Eisenberg (3), with the following modifications. Briefly, after the trabecula had reached steady-state force, the motor arm was rapidly moved to slacken the trabecula by 10%. After 50 ms of shortening, the motor arm swung rapidly backward so as to pass the original set point (10% overshoot stretch) and then rapidly returned to the original set point. After each experiment, fibers were collected and stored in 1% SDS solution and frozen at –20°C for later analysis by SDS-PAGE.

Gel electrophoresis. Cardiac {alpha}- and {beta}-MHC isoforms were electrophoretically separated on 1.5-mm-thick, 14-cm-wide, and 16-cm-long gels with a Hoefer SE 600 system (Hoefer Scientific) and the Laemmli gel system (22) with minor modifications. The acrylamide solution used to make 6.5% resolving gels and 5% stacking gels contained 25% acrylamide and 0.25% bis-acrylamide (12). Acrylamide solutions were degassed for 10–15 min and polymerized by adding 10% ammonium persulfate and N,N,N',N'-tetramethylethylenediamine (Bio-Rad) to final concentrations of 0.125% (wt/vol) and 0.05% (vol/vol), respectively. Resolving gels were polymerized at room temperature and stored overnight at 4°C. Stacking gels were polymerized for at least 30 min. Lanes were formed with 1.5-mm-thick, 10-well combs. Samples were prepared by dilution with extraction buffer to 0.5 µg protein/µl, and bromophenol blue was added to a final concentration of 0.01%. Extraction buffer consisted of 50 mM Tris pH 6.8, 2.5% SDS, 10% glycerol, 1 mM DTT, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 mM PMSF, and 5 µg/ml aprotinin. Samples were boiled for 3 min before loading of 5 µg of total protein per well. Gel and running buffer composition was as described by Laemmli (22). The running buffer was precooled to 4°C before the samples were loaded. 2-Mercaptoethanol was added to a final concentration of 6.23 mM (800 µl/l) to the upper running buffer. Electrophoresis was performed at constant current, with 25 mA/gel for 20 min, followed by 45 mA/gel for 5–7 h for murine, human, baboon, rodent, and porcine samples. Frozen human atrial and ventricular tissues were the kind gift of Dr. R. J. Solaro. Rabbit and guinea pig samples could be best separated with electrophoresis for 20 min at 25 mA/gel, followed by 30 mA/gel for 14 h. Examples of MHC separation from these species with these electrophoretic conditions are illustrated in Fig. 2. Gels were cooled during the run by a circulating bath (Fisher Isotemp) set to 2°C to obtain a temperature of 1–2°C in the circulating bath and 4–6°C in the running buffer at the end of the run. Running buffer was stirred throughout electrophoresis with a magnetic stirring bar. At the completion of electrophoresis, gels were removed, stained with 0.03% Coomassie blue stain or Pierce Gel Code Blue stain for 2–16 h according to manufacturer's instructions. Gels were scanned with a Bio-Rad GS 710 flatbed scanner and analyzed with Kodak 1D software.



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2. Representative gels and densitometric scans of the separation of cardiac {alpha}- and {beta}-myosin heavy chain (MHC) isoforms. A: baboon, human, and pig. B: ventricular extracts from rat and mouse ± treatment with PTU for a period of 4–6 wk. C: rabbit and guinea pig. a, Atrium; v, ventricle.

 
Data analysis. The results of the mechanical experiments were fit to a modified Hill equation: F = Fmax x [Ca2+]nH/([Ca2+]nH+ EC50nH), where F is peak steady-state force (skinned), Fmax is the maximum saturated value F can attain; EC50 is the concentration of Ca2+ ([Ca2+]) at which F is 50% of Fmax, and nH is the Hill coefficient and represents the slope of the force-[Ca2+] relation at EC50. Each experimental trabecula was fit individually, these fit parameters were pooled, and the mean values are reported. Consumption of ATP was normalized to muscle volume and plotted vs. the force/cross-sectional area attained during each contraction. Linear regression was used to fit this relationship, the slope of each experimental line fit was pooled, and the mean value is reported as tension cost. The ktr was calculated as a single-exponential fit of the initial rate of rise in tension following a rapid release-restretch maneuver as previously described (cf. Fig. 1, B and C, and Ref. 3). Individual fits were pooled to generate the mean value reported. Numbers (n) of trabeculae for each group studied were 10 (6 days), 11 (11 days), 9 (16 days), and 9 (21 days). These numbers reflect the total number of animals studied, as only one muscle per animal was used. Data were analyzed by ANOVA, and significance is reported at P < 0.05 with a commercially available statistical package (SPSS 10.0).


    RESULTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Characterization of model. Physical parameters of the animals used in the study are summarized in Table 1. The largest length of time animals were treated with PTU was 3 wk. There was no alteration in body weight, heart weight, or the heart weight-to-body weight ratio between groups. This indicates that there were no deleterious effects of PTU treatment on heart or body size in this short-term PTU treatment study.


View this table:
[in this window]
[in a new window]
 
Table 1. Physical parameters of PTU model

 
MHC isoform expression. The utility of PTU treatment for increasing the level of cardiac {beta}-MHC expression has been well characterized (34). To assess the relative cardiac MHC isoform content we subjected all muscles to SDS-PAGE, as described in METHODS. The method we describe for separating cardiac {alpha}- and {beta}-MHC is a modification of the Laemmli gel system that allows separation of the MHC isoforms in 6 h and permits gel staining by Coomassie blue. We did not find that the addition of glycerol improved the protein separation (35). After staining, gels were optically scanned with a densitometer and relative protein content was determined with analytical software (Kodak ID). The relative amounts of the two cardiac MHC isoforms could be quantified readily because all samples had at least 1.0 mm of separation from peak to peak in the densitometric scans. An example of the separation is shown in Fig. 3A. Rats treated with PTU had a significant and progressive decrease in {alpha}-MHC myocardial protein content with length of PTU treatment (68 ± 5%, 58 ± 4%, 37 ± 4%, and 27 ± 6% for 6, 11, 16, and 21 days of PTU, respectively; P < 0.001 by ANOVA), as illustrated in Fig. 3B. There was no indication that total MHC content was affected by PTU treatment.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3. {alpha}-MHC content decreases with length of PTU treatment. A: sample of MHC separation in PTU study. There is a decreasing amount of {alpha}-MHC content associated with increasing length of treatment with PTU. B: mean values obtained from MHC separation by SDS-PAGE. There is a significant and progressive decrease in {alpha}-MHC content as length of PTU treatment increases. *P < 0.001 by ANOVA.

 
Mechanical impact of hypothyroidism in RV skinned fibers. Fibers were subjected to a series of calcium-activated contractions, and the data were fit to a modified Hill equation as described in METHODS. The mean Hill fit parameters from each individual fiber experiment are reported in Table 2. Figure 4A illustrates the mean data collected in the 6- and 21-day PTU groups. As can be seen, maximal calcium-activated myofilament tension development was not significantly different between groups, indicating that PTU treatment did not have any deleterious effects on the force-generating capability of the contractile proteins. Furthermore, there were no changes in myofilament calcium sensitivity as indexed by the [Ca2+] at which force is half-maximal (EC50) between groups with increasing length of PTU treatment. Therefore, PTU treatment did not have any impact on the contractile filament's sensitivity to calcium. Additionally, there were no differences in nH between groups with increased length of PTU treatment, indicating that there was no change in the cooperativity of thin filament activation. Thus PTU treatment had no deleterious effects on myocardial mechanics in this short-term (maximum 21 days) PTU treatment model.


View this table:
[in this window]
[in a new window]
 
Table 2. Mean fit parameters from individual Hill fits to data

 


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4. Mean representations of mechanical data in 6- and 21-day PTU-treated animals. Data from 6-day PTU are denoted by solid circles and solid line, data from 21-day PTU are denoted by open circles and dashed line. A: mean tension-calcium relationship at 6 and 21 days of PTU. There was no change in maximal force development, myofilament sensitivity to calcium, or Hill coefficient, indicating that PTU treatment did not affect these measures of myofilament contraction. B: mean tension-dependent ATP consumption relationship at 6 and 21 days of PTU. There was a dramatic decline in the slope of this relationship, the tension cost, with increased time of PTU treatment, indicating a lower cross-bridge rate of detachment in the 21-day PTU group. C: mean tension-dependent stiffness relationship at 6 and 21 days of PTU. There were no differences in the high-frequency stiffness, indicating that the force per cross bridge was unchanged with increasing length of PTU treatment.

 
Cross-bridge cycling kinetics are depressed in hypothyroid cardiac fibers. The two-state model of cross-bridge cycling predicts that the overall steady-state rate of the cross-bridge cycle is proportional to the overall flux of either cross-bridge attachment or detachment (2, 20). Force is determined by the fraction of attached cross bridges and the force per cross bridge. A two-state model predicts that the fraction of attached cross bridges is proportional to the first-order rate constant of attachment (f) divided by the sum of f and the first-order rate constant of detachment (g), i.e., f/(f + g). ATP consumption is proportional to the product of the number of attached cross bridges and g, i.e., g x f/(f + g). Tension cost is equal to the ATP consumption divided by force, which is therefore directly proportional to g (4, 20). To assess the impact of PTU treatment on cross-bridge cycling kinetics, we determined tension cost in all groups. All measures of cross-bridge cycling kinetics were significantly and progressively depressed with continued administration of PTU. The mean data are summarized in Table 3, and Fig. 4B illustrates the difference in tension cost measured in the 6- and 21-day PTU groups. Maximal ATP consumption rate was significantly and progressively reduced with increased length of PTU treatment (P < 0.01). Likewise, tension cost, the measure of steady-state cross-bridge detachment, was also progressively depressed with length of PTU administration (P < 0.01). Dynamic cross-bridge turnover, flux through the cross-bridge cycle (f + g), can be assessed by the ktr following a rapid release restretch maneuver in saturating calcium aimed to disengage all attached cross bridges (3). The subsequent rise in tension was fit with a single-exponential equation. The mean values for ktr are given in Table 3, and it is clear that ktr was significantly and progressively depressed with increased length of PTU treatment (P < 0.001).


View this table:
[in this window]
[in a new window]
 
Table 3. Mean measures of cross-bridge cycling kinetics

 
Cross-bridge cycling kinetics are depressed linearly with decreasing {alpha}-MHC. Considering that PTU treatment results in decreasing {alpha}-MHC content and that this subsequently reduces cross-bridge cycling rate, it is important to determine whether this depression is a linear function of isoform expression. Therefore, we plotted the relative {alpha}-MHC content of each fiber vs. the measured tension cost and ktr values for the fiber. Figure 5 illustrates that, indeed, the relationships between {alpha}-MHC content and tension cost and ktr are linear. Additionally, as this relationship is linear, and if we can assume that thick filaments will be composed of random arrangements of {alpha}- and {beta}-MHC homo- and heterodimers, at points between the extremes, this indicates that there is no effect of {beta}-MHC cross bridges on those of {alpha}-MHC. That is to say, the longer cycle time of {beta}-MHC cross bridges does not slow down the cycle time of {alpha}-MHC cross bridges to any measurable degree in isometrically contracting skinned fiber preparations.



View larger version (9K):
[in this window]
[in a new window]
 
Fig. 5. Mean tension cost and ktr decrease linearly with decreasing {alpha}-MHC content. A: mean tension cost plotted vs. mean densitometrically determined {alpha}-MHC content and fit with a line (R = 0.98). B: mean ktr plotted vs. mean densitometrically determined {alpha}-MHC content and fit with a line (R = 0.97).

 

    DISCUSSION
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
There were no detrimental effects of increased {beta}-MHC expression on the force-generating capability of skinned RV trabeculae in the rat. Also, the myofilament sensitivity for calcium as indexed by the EC50 was not altered with increased length of PTU treatment in this study. These data are in agreement with our previously published work (6) and that of others (11, 17) in the PTU-treated rat. In contrast, there are reports of decreased myofilament sensitivity for calcium in the mature guinea pig and PTU-treated rat, both of which had very high levels of {beta}-MHC isoform expression (29, 41). Van der Velden and colleagues (41) report a shift in the EC50 of calcium between treatment groups of 0.80 µM, and Metzger and colleagues (29) report an even greater shift in EC50 (1.01 µM) after 6 wk of PTU treatment in the rat. The reasons behind the discrepancy are unclear, however.

The widespread use of rodent models of cardiac disease has prompted a reinvestigation of the effects of MHC isoform shifts in measures of cardiac contractility and energetics, where the confounding effect of MHC switching has a significant impact. As discussed above, {alpha}-MHC is the predominant isoform expressed in rodent cardiac tissue, as opposed to {beta}-MHC in human myocardium; however, during the course of disease development, regardless of etiology, {beta}-MHC becomes more highly expressed. This is seen as an adaptive mechanism initially, in that {beta}-MHC is the more economical ATPase and has at least the same, if not greater, force-generating capability as {alpha}-MHC (37, 40). However, the unloaded velocity of shortening of this isoform ({beta}-MHC) is considerably less, and recent evaluation of cells expressing only {beta}-MHC indicated a considerable deficit not only in loaded shortening velocity but also in overall power output-generating capacity (5, 17, 33). Thus increasing the {beta}-MHC content in myocardium can have a deleterious effect on myocardial contractility. This was further demonstrated by using a transgenic approach to express a small amount of {beta}-MHC (12%), without alteration of thyroid state, in mouse myocardium. The resultant effect was a 25% decrease in myofibrillar ATPase activity and a 15% decrease in systolic function measured as developed pressure in a Langendorff-perfused heart preparation (39). Furthermore, recent studies in human cardiac tissue have demonstrated that {alpha}-MHC RNA is not only transcribed but also translated, comprising ~7% of the total MHC content in normal human myocardium, whereas there is virtually no {alpha}-MHC RNA and undetectable amounts of protein in failing myocardium (30, 31). Thus it seems that small perturbations in MHC isoform expression can lead to severe deleterious consequences in pump function of the working heart, despite perhaps little alteration in maximal myofilament force-generating capability.

An inordinate slowing of the maximum sliding filament velocity of {alpha}-MHC populations when small increments of {beta}-MHC are present in the in vitro motility assay has been reported (15). The data of these experiments reflect a curvilinear MHC-velocity relationship in which the velocity of actin filaments slows increasingly as more {beta}-MHC is added to the preparation. Harris and colleagues (15) surmised that the slower ATPase of {beta}-MHC was causing a drag effect on the {alpha}-MHC cross bridges as a result of their longer duty cycle. However, those experiments measured unloaded cross-bridge cycling and also had little control regarding orientation of myosin heads in regard to actin filament position. Under isometric conditions we have determined that there is no effect of {beta}-MHC cross bridges on {alpha}-MHC cross bridges, as evidenced by the linear shape of both the {alpha}-MHC vs. tension cost and {alpha}-MHC vs. ktr relationships. Furthermore, because we found no differences in the high-frequency stiffness vs. tension relationship (see Table 3 and Fig. 4C), we can assume that force per cross bridge was not altered in this model. Thus the differences in cross-bridge cycling kinetics we have observed are limited to the inherent kinetic properties of the MHC isoforms, and not their force-generating capacity. This result indicates that isometrically cycling cross bridges act independently, that is, each cross bridge hydrolyzing ATP at its intrinsic rate governed solely by its individual MHC isoform.

PTU had the effect of progressively lowering the myocardial content of {alpha}-MHC in otherwise healthy, young rodents. Commensurate with this decreased expression was a decrease of all cross-bridge cycling parameters measured, including total ATP consumption rate, tension cost, and ktr. By extrapolation of the linear curve fit we were able to derive that there was a 2.5- to 3-fold reduction in cross-bridge cycling rate as indexed by tension cost and ktr. The linear decrease in tension cost with increasing {beta}-MHC content is in accordance with previously published work in the guinea pig (41). However, the difference in tension cost at nearly 100% {beta}-MHC expression from that measured at 100% {alpha}-MHC expression that we report in the rat (3 times less at 100% {beta}-MHC) is lower than that reported for the guinea pig (5 times less at 100% {beta}-MHC). It may be that the discrepancy lies in the narrow range of MHC isoforms investigated in that study and the need to extrapolate those data to cover the range from 30% to 100% {alpha}-MHC content (41). We have determined here and previously (6) that the force-calcium relationship is unchanged with increasing expression of {beta}-MHC. We assume that the force per cross bridge between conditions is unchanged, as supported by the finding that the relationship between high-frequency stiffness and force development was not affected by PTU treatment. As described above, tension cost is proportional to g and ktr is equal to (f + g), and we find that both are decreasing by a factor of 3. If we then apply the two-state cross-bridge model of contraction described by Brenner (2), we are able to derive that not only gapp, but also fapp, decreases approximately three times in the transition from 100% {alpha}-MHC to 100% {beta}-MHC. The fapp would necessarily be decreased by three times, to result in a proportional decrease in both tension cost and ktr while maintaining isometric tension development at the same level.

Limitations of study. We (5) and others (29) have shown that administration of PTU results in a dramatic decrease in the circulating levels of T3 and thyroxine, although these values were not measured in the present study. Furthermore, with respect to the myofilament proteins, it has been extensively reported that only MHC isoform expression is altered with PTU treatment (11, 17, 29). However, we did not investigate the possibility of other myofilament protein alteration, and, as such, it cannot be completely excluded. It is known that there is significant alteration of {beta}-adrenergic receptor and calcium-handling protein expression in the PTU-treated rat; however, this study investigated skinned muscle, where there would be no difference in calcium delivery to or adrenergic regulation of the myofilaments. Hence, we do not anticipate that these factors affected our conclusions. Also, there was no measurement of SL during the course of the ktr; however, it was examined before and after the maneuver, and the preparation was discarded if the SL deviated from its set point of 2.3 µm. Wolff and colleagues (43) examined the ktr in cardiac muscle under conditions of strict SL control and found that lack of SL control resulted in ~10% underestimation of ktr. Hence, we cannot exclude that the ktr measurements were slightly underestimated. However, this would apply to all muscles in all groups, and therefore in our study this factor would not alter our main finding of an approximately three times slower ktr in {beta}-MHC as opposed to {alpha}-MHC myocardium.

The experiments presented here confirm earlier work and expand the scope of our understanding of the impact of MHC isoform expression on cardiac energetics to include intermediate points in the transition from 100% {alpha}-MHC content to 100% {beta}-MHC content. This enabled us to conclude accurately that there exists a linear relationship between cross-bridge cycling kinetics and MHC isoform expression.


    GRANTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This work was supported by National Institutes of Health (NIH) Grants HL/DK-R01–63704 and HL-P01-62426 (P. P. de Tombe) and also HL-64942 (A. F. Martin). V. L. M. Rundell received NIH support through institutional training grants (T32-HL-07692 and T32-HL-072742).


    ACKNOWLEDGMENTS
 
The authors thank Dr. John Walker for valuable discussions of the data and Dr. R. John Solaro for the human tissue samples used in the electrophoretic studies.


    FOOTNOTES
 

Address for reprint requests and other correspondence: P. P. de Tombe, 835 S Wolcott M/C 901, Chicago, IL 60612 (E-mail: pdetombe{at}uic.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Barany M. ATPase activity of myosin correlated with speed of muscle shortening. J Gen Physiol 50: 197–210, 1967.[Abstract/Free Full Text]
  2. Brenner B. Effect of Ca2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers: implications for regulation of muscle contraction. Proc Natl Acad Sci USA 85: 3265–3269, 1988.[Abstract/Free Full Text]
  3. Brenner B and Eisenberg E. Rate of force generation in muscle: correlation with actomyosin ATPase activity in solution. Proc Natl Acad Sci USA 83: 3542–3546, 1986.[Abstract/Free Full Text]
  4. De Tombe PP and Stienen GJ. Protein kinase A does not alter economy of force maintenance in skinned rat cardiac trabeculae. Circ Res 76: 734–741, 1995.[Abstract/Free Full Text]
  5. De Tombe PP and ter Keurs HEDJ. Lack of effect of isoproterenol on unloaded velocity of sarcomere shortening in rat cardiac trabeculae. Circ Res 68: 382–391, 1991.[Abstract/Free Full Text]
  6. De Tombe PP, Wannenburg T, Fan D, and Little WC. Right ventricular contractile protein function in rats with left ventricular myocardial infarction. Am J Physiol Heart Circ Physiol 271: H73–H79, 1996.[Abstract/Free Full Text]
  7. Ebus JP and Stienen GJ. Origin of concurrent ATPase activities in skinned cardiac trabeculae from rat. J Physiol 492: 675–687, 1996.[Abstract/Free Full Text]
  8. Elzinga G and Westerhof N. Matching between ventricle and arterial load: an evolutionary process. Circ Res 68: 1495–1500, 1991.[Abstract/Free Full Text]
  9. Everett AW, Sinha AM, Umeda PK, Jakovcic S, Rabinowitz M, and Zak R. Regulation of myosin synthesis by thyroid hormone: relative change in the {alpha}- and {beta}-myosin heavy chain mRNA levels in rabbit heart. Biochemistry 23: 1596–1599, 1984.[CrossRef][Medline]
  10. Fabiato A and Fabiato F. Calculator programs for computing the composition of the solutions containing multiple metals and ligands used for experiments in skinned muscle cells. J Physiol (Paris) 75: 463–505, 1979.[Medline]
  11. Fitzsimons DP, Patel JR, and Moss RL. Role of myosin heavy chain composition in kinetics of force development and relaxation in rat myocardium. J Physiol 513: 171–183, 1998.[Abstract/Free Full Text]
  12. Giulian GG, Moss RL, and Greaser M. Improved methodology for analysis and quantitation of proteins on one-dimensional silver-stained slab gels. Anal Biochem 129: 277–287, 1983.[CrossRef][Web of Science][Medline]
  13. Glyn H and Sleep J. Dependence of adenosine triphosphate activity of rabbit psoas muscles fibres and myofibrils on substrate concentrations. J Physiol 365: 259–276, 1985.[Abstract/Free Full Text]
  14. Gorza L, Pauletto P, Pessina AC, Sartore S, and Schiaffino S. Isomyosin distribution in normal and pressure-overloaded rat ventricular myocardium. Circ Res 49: 1003–1009, 1981.[Abstract/Free Full Text]
  15. Harris DE, Work SS, Wright RK, Alpert NR, and Warshaw DM. Smooth, cardiac and skeletal muscle myosin force and motion generation assessed by cross-bridge mechanical interactions in vitro. J Muscle Res Cell Motil 15: 11–19, 1994.[CrossRef][Web of Science][Medline]
  16. Hasenfuss G, Mulieri LA, Blanchard EM, Holubarsch C, Leavitt BJ, Ittleman F, and Alpert NR. Energetics of isometric force development in control and volume-overload human myocardium. Comparison with animal species. Circ Res 68: 836–846, 1991.[Abstract/Free Full Text]
  17. Herron TJ, Korte FS, and McDonald KS. Loaded shortening and power output in cardiac myocytes are dependent on myosin heavy chain isoform expression. Am J Physiol Heart Circ Physiol 281: H1217–H1222, 2001.[Abstract/Free Full Text]
  18. Herron TJ and McDonald KS. Small amounts of {alpha}-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res 90: 1150–1152, 2002.[Abstract/Free Full Text]
  19. Hoh JF, McGrath PA, and Hale PT. Electrophoretic analysis of multiple forms of rat cardiac myosin: effects of hypophysectomy and thyroxine replacement. J Mol Cell Cardiol 10: 1053–1076, 1978.[CrossRef][Web of Science][Medline]
  20. Huxley AF. Muscle structure and theories of contraction. Prog Biophys Biophys Chem 7: 255–318, 1957.[Medline]
  21. Katzung BG and Trevor AJ. Pharmacology Examination and Board Review. Norwalk, CT: Lange, 1995.
  22. Laemmli UK. Cleavage of structural proteins during the assembly of the head bacteriophage T4. Nature 227: 680–685, 1970.[CrossRef][Medline]
  23. Martin AF, Haithcoat JL, and Dowell RT. Redistribution of ventricular myosin isoenzymes in neonatal and adult rat heart in response to chronic pressure overload. Perspect Cardiovasc Res 7: 359–371, 1983.
  24. Martin AF, Phillips RM, Kumar A, Crawford K, Abbas Z, Lessard JL, de Tombe PP, and Solaro RJ. Ca2+ activation and tension cost in myofilaments from mouse hearts ectopically expressing enteric {gamma}-actin. Am J Physiol Heart Circ Physiol 283: H642–H649, 2002.[Abstract/Free Full Text]
  25. Martin AF, Rabinowitz M, Blough R, Prior G, and Zak R. Measurements of half-life of rat cardiac myosin heavy chain with leucyl-tRNA used as precursor pool. J Biol Chem 252: 3422–3429, 1977.[Abstract/Free Full Text]
  26. McNally EM, Kraft R, Bravo-Zehnder M, Taylor DA, and Leinwand LA. Full-length rat {alpha} and {beta} cardiac myosin heavy chain sequences. Comparisons suggest a molecular basis for functional differences. J Mol Biol 210: 665–671, 1989.[CrossRef][Web of Science][Medline]
  27. Mercadier JJ, Bouverett P, Gorza L, Schiaffino S, Clark WA, Zak R, Swynghedauw B, and Schwartz K. Myosin isoenzymes in normal and hypertrophied human ventricular myocardium. Circ Res 53: 52–62, 1983.[Abstract/Free Full Text]
  28. Mercadier JJ, Lompre AM, Wisnewsky C, Samuel JL, Bercovici J, Swynghedauw B, and Schwartz K. Myosin isoenzymic changes in several models of rat cardiac hypertrophy. Circ Res 49: 525–532, 1981.[Abstract/Free Full Text]
  29. Metzger JM, Wahr PA, Michele DE, Albayya F, and Westfall MV. Effects of myosin heavy chain isoform switching on Ca2+-activated tension development in single adult cardiac myocytes. Circ Res 84: 1310–1317, 1999.[Abstract/Free Full Text]
  30. Miyata S, Minobe W, Bristow MR, and Leinwand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 86: 386–390, 2000.[Abstract/Free Full Text]
  31. Nakao K, Minobe W, Roden R, Bristow MR, and Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest 100: 2362–2370, 1997.[Web of Science][Medline]
  32. Naya T, Manaves V, Mori Y, Daniels MCG, Rundell VLM, and de Tombe PP. Cross-bridge cycling rate during the development of heart failure. Biophys J 78: 108A, 2000.
  33. Pagani ED and Julian FJ. Rabbit papillary muscle myosin isozymes and the velocity of muscle shortening. Circ Res 54: 586–594, 1984.[Abstract/Free Full Text]
  34. Pope B, Hoh JF, and Weeds A. The ATPase activities of rat cardiac myosin isoenzymes. FEBS Lett 118: 205–208, 1980.[CrossRef][Web of Science][Medline]
  35. Reiser PJ and Kline WO. Electrophoretic separation and quantitation of cardiac myosin heavy chain isoforms in eight mammalian species. Am J Physiol Heart Circ Physiol 274: H1048–H1053, 1998.[Abstract/Free Full Text]
  36. Schwartz K, Lecarpentier Y, Martin JL, Lompre AM, Mercadier JJ, and Swynghedauw B. Myosin isoenzymic distribution correlates with speed of myocardial contraction. J Mol Cell Cardiol 13: 1071–1075, 1981.[CrossRef][Web of Science][Medline]
  37. Sugiura S, Kobayakawa N, Fujita H, Yamashita H, Momomura S, Chaen S, Omata M, and Sugi H. Comparison of unitary displacements and forces between 2 cardiac myosin isoforms by the optical trap technique: molecular basis for cardiac adaptation. Circ Res 82: 1029–1034, 1998.[Abstract/Free Full Text]
  38. Swynghedauw B. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscle. Physiol Rev 66: 710–771, 1986.[Abstract/Free Full Text]
  39. Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J, and Leinwand LA. Expression of the {beta} (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol 278: H412–H419, 2000.[Abstract/Free Full Text]
  40. VanBuren P, Harris DE, Alpert NR, and Warshaw DM. Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. Circ Res 77: 439–444, 1995.[Abstract/Free Full Text]
  41. Van der Velden J, Moorman AF, and Stienen GJ. Age-dependent changes in myosin composition correlate with enhanced economy of contraction in guinea-pig hearts. J Physiol 507: 497–510, 1998.[Abstract/Free Full Text]
  42. Westerhof N and Elzinga G. Normalized input impedance and arterial decay time over heart period are independent of animal size. Am J Physiol Regul Integr Comp Physiol 261: R126–R133, 1991.[Abstract/Free Full Text]
  43. Wolff MR, McDonald KS, and Moss RL. Rate of tension development in cardiac muscle varies with level of activator calcium. Circ Res 76: 154–160, 1995.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Circ Heart FailHome page
T. Suzuki, B. M. Palmer, J. James, Y. Wang, Z. Chen, P. VanBuren, D. W. Maughan, J. Robbins, and M. M. LeWinter
Effects of Cardiac Myosin Isoform Variation on Myofilament Function and Crossbridge Kinetics in Transgenic Rabbits
Circ Heart Fail, July 1, 2009; 2(4): 334 - 341.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. R. Locher, M. V. Razumova, J. E. Stelzer, H. S. Norman, J. R. Patel, and R. L. Moss
Determination of rate constants for turnover of myosin isoforms in rat myocardium: implications for in vivo contractile kinetics
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H247 - H256.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. P. Flagg, O. Cazorla, M. S. Remedi, T. E. Haim, M. A. Tones, A. Bahinski, R. E. Numann, A. Kovacs, J. E. Schaffer, C. G. Nichols, et al.
Ca2+-Independent Alterations in Diastolic Sarcomere Length and Relaxation Kinetics in a Mouse Model of Lipotoxic Diabetic Cardiomyopathy
Circ. Res., January 2, 2009; 104(1): 95 - 103.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
J. E. Stelzer, H. S. Norman, P. P. Chen, J. R. Patel, and R. L. Moss
Transmural variation in myosin heavy chain isoform expression modulates the timing of myocardial force generation in porcine left ventricle
J. Physiol., November 1, 2008; 586(21): 5203 - 5214.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. B. Pillai, M. Chen, S. B. Rajamohan, S. Samant, V. B. Pillai, M. Gupta, and M. P. Gupta
Activation of SIRT1, a class III histone deacetylase, contributes to fructose feeding-mediated induction of the {alpha}-myosin heavy chain expression
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1388 - H1397.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Hamdani, V. Kooij, S. van Dijk, D. Merkus, W. J. Paulus, C. d. Remedios, D. J. Duncker, G. J.M. Stienen, and J. van der Velden
Sarcomeric dysfunction in heart failure
Cardiovasc Res, March 1, 2008; 77(4): 649 - 658.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. P. Davis and S. B. Tikunova
Ca2+ exchange with troponin C and cardiac muscle dynamics
Cardiovasc Res, March 1, 2008; 77(4): 619 - 626.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
F. Haddad, A. X. Qin, P. W. Bodell, W. Jiang, J. M. Giger, and K. M. Baldwin
Intergenic transcription and developmental regulation of cardiac myosin heavy chain genes
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H29 - H40.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Chandra, M. L. Tschirgi, S. J. Ford, B. K. Slinker, and K. B. Campbell
Interaction between myosin heavy chain and troponin isoforms modulate cardiac myofiber contractile dynamics
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1595 - R1607.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
I. F. Edes, D. Czuriga, G. Csanyi, S. Chlopicki, F. A. Recchia, A. Borbely, Z. Galajda, I. Edes, J. van der Velden, G. J. M. Stienen, et al.
Rate of tension redevelopment is not modulated by sarcomere length in permeabilized human, murine, and porcine cardiomyocytes
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R20 - R29.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. C. G. Daniels, T. Naya, V. L. M. Rundell, and P. P. de Tombe
Development of contractile dysfunction in rat heart failure: hierarchy of cellular events
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R284 - R292.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
F. S. Korte and K. S. McDonald
Sarcomere length dependence of rat skinned cardiac myocyte mechanical properties: dependence on myosin heavy chain
J. Physiol., June 1, 2007; 581(2): 725 - 739.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
J. E. Stelzer, S. L. Brickson, M. R. Locher, and R. L. Moss
Role of myosin heavy chain composition in the stretch activation response of rat myocardium
J. Physiol., February 15, 2007; 579(1): 161 - 173.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
B. Schoffstall, N. M. Brunet, S. Williams, V. F. Miller, A. T. Barnes, F. Wang, L. A. Compton, L. A. McFadden, D. W. Taylor, M. Seavy, et al.
Ca2+ sensitivity of regulated cardiac thin filament sliding does not depend on myosin isoform
J. Physiol., December 15, 2006; 577(3): 935 - 944.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. J. Herron, E. Rostkova, G. Kunst, R. Chaturvedi, M. Gautel, and J. C. Kentish
Activation of Myocardial Contraction by the N-Terminal Domains of Myosin Binding Protein-C
Circ. Res., May 26, 2006; 98(10): 1290 - 1298.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. C. Hinken and K. S. McDonald
{beta}-Myosin heavy chain myocytes are more resistant to changes in power output induced by ischemic conditions
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H869 - H877.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. E. Montgomery, V. L. M. Rundell, P. H. Goldspink, D. Urboniene, D. L. Geenen, P. P. de Tombe, and P. M. Buttrick
Protein kinase C{varepsilon} induces systolic cardiac failure marked by exhausted inotropic reserve and intact Frank-Starling mechanism
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1881 - H1888.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. M. Arteaga, C. M. Warren, S. Milutinovic, A. F. Martin, and R. J. Solaro
Specific enhancement of sarcomeric response to Ca2+ protects murine myocardium against ischemia-reperfusion dysfunction
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2183 - H2192.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
F. S. Korte, T. J. Herron, M. J. Rovetto, and K. S. McDonald
Power output is linearly related to MyHC content in rat skinned myocytes and isolated working hearts
Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H801 - H812.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
D. T. Corr and W. Herzog
Force recovery after activated shortening in whole skeletal muscle: transient and steady-state aspects of force depression
J Appl Physiol, July 1, 2005; 99(1): 252 - 260.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/2/H896    most recent
00407.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rundell, V. L. M.
Right arrow Articles by de Tombe, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rundell, V. L. M.
Right arrow Articles by de Tombe, P. P.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.